Accelerated target identification using preclinical neuroimaging to close the treatment gap in Obsessive Compulsive Disorder (started 01/09/2015).
Development of clinically-feasible strategies for more accurate quantification of amyloid-beta scans (started 01/10/2015).
Combining small animal molecular imaging with next generation neuromodulation to explore novel OCD treatments (01/10/2014 -30/09/2018).
Sven De Bruycker
Predictive imaging biomarkers for drugs targeting the tumor microenvironment in lung cancer (1/10/2013 - 30/09/2017).
Molecular imaging for early response assessment of drugs targeting the PI3K/Akt/mTOR pathway in an HER-2 amplified breast cancer model (1/10/2012 - 30/09/2016)
Development and in vivo evaluation of SPECT/PET tracers for cell death imaging for the assessment of early tumor cell death in response to therapy
PET imaging as a potential biomarker for the diagnosis and treatment in Alzheimer’s disease
Multimodal molecular imaging of a rat model for schizophrenia contributing to an integrative understanding of the glutamatergic (mGluR5), neuroinflammatory (TSPO) and phosphodiesterase (PDE10) interplay
Alan Miranda Menchaca
Molecular brain imaging of unanesthetized and unconstrained small animals (1/10/2013 - 30/09/2017)
The role of extracellular matrix proteases MMP-9 and uPA in the development of posttraumatic epilepsy following traumatic brain injury (1/10/2013 - 30/09/2017)
Molecular imaging for early response assessment of drugs targeting the PI3K/Akt/mTOR pathway in a colorectal cancer model (1/10/2012 – 30/09/2016)
Development of an in vivo microPET imaging platform for the non-invasive investigation of novel therapeutics in Alzheimer's disease (1/01/2014 - 31/12/2017)
Characterization of brain inflammation in a chronic epilepsy model by means of post-mortem and in vivo techniques (1/10/2011- 31/12/2015)